A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects

A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other tha...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical infectious diseases Ročník 36; číslo 10; s. 1221
Hlavní autoři:	Rex, John H, Pappas, Peter G, Karchmer, Adolf W, Sobel, Jack, Edwards, John E, Hadley, Susan, Brass, Corstiaan, Vazquez, Jose A, Chapman, Stanley W, Horowitz, Harold W, Zervos, Marcus, McKinsey, David, Lee, Jeannette, Babinchak, Timothy, Bradsher, Robert W, Cleary, John D, Cohen, David M, Danziger, Larry, Goldman, Mitchell, Goodman, Jesse, Hilton, Eileen, Hyslop, Newton E, Kett, Daniel H, Lutz, Jon, Rubin, Robert H, Scheld, W Michael, Schuster, Mindy, Simmons, Bryan, Stein, David K, Washburn, Ronald G, Mautner, Linda, Chu, Teng-Chiao, Panzer, Helene, Rosenstein, Rebecca B, Booth, Jenia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.05.2003
Témata:	Adult Amphotericin B - adverse effects Amphotericin B - therapeutic use Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Candida - drug effects Candidiasis - drug therapy Candidiasis - physiopathology Catheterization Double-Blind Method Drug Therapy, Combination Female Fluconazole - adverse effects Fluconazole - therapeutic use Fungemia - drug therapy Fungemia - physiopathology Humans Male Middle Aged Neutropenia - etiology Treatment Outcome
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean (+/- standard error) Acute Physiology and Chronic Health Evaluation II score (16.8+/-0.6 vs. 15.0+/-0.7; P=.039). Success rates on study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB (P=.08). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 patients; P=.043), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respectively (P=.02). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	1537-6591 1537-6591
DOI:	10.1086/374850